Cover Image
Market Research Report
Product code 
1040076

Liquid Biopsy Market by Product (Assay Kits, Instruments, Service), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-Cancer), End User (Reference Lab, Hospitals) - Global Forecast to 2026

Published: | MarketsandMarkets | 225 Pages | Delivery time: 1-2 business days

Price

Back to Top
Liquid Biopsy Market by Product (Assay Kits, Instruments, Service), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-Cancer), End User (Reference Lab, Hospitals) - Global Forecast to 2026
Published: November 30, 2021
MarketsandMarkets
Content info: 225 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

The global liquid biopsy market is projected to reach USD 5.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 18.1% during the forecast period. Market growth is driven by factors such as the rising incidence & prevalence of cancerand the increasing preference for noninvasive treatment procedures. On the other hand, the lower sensitivity of certain liquid biopsies might act as a restraining factor to the growth of this market.

"The assay kits segment accounted for the highest growth rate in theliquid biopsy market, by product& service, during the forecast period"

The liquid biopsy market is segmented into assay kits, instruments, and services based on product & service. In 2020, the assay kits segment accounted for the highest growth rate in the liquid biopsy market. The availability of a wide range of reagents and kits, easy accessibility to a wide range of assays, and the rising prevalence of cancer are the major factors driving the growth of the liquid biopsy assay kits market.

"Non-cancer applicationssegment accounted for the highest CAGR"

Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications. In 2020, the non-cancer application segment accounted for the highest growth rate. This can be attributed to the increasing research activities in NIPT and organ transplant diagnosis.

"Asia Pacific: The fastest-growing regionliquid biopsymarket"

The global liquid biopsymarket is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period.

The Asia Pacific region is projected to register the highest CAGR during the forecast period.Factors such as government efforts to increase awareness about the early detection of diseases and regular health check-ups, continuously rising healthcare expenditure, increasing number of hospitals, clinical diagnostic laboratories in India and China, and strengthening research base for diagnostic procedures across India, China, and Japanare expected to boost the market growth. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa - 4%

Lists of Companies Profiled in the Report:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Myriad Genetics, Inc. (US)
  • QIAGEN N.V. (Netherlands)
  • Thermo Fisher Scientific, Inc. (US)
  • Guardant Health, Inc. (US)
  • MDxHealth SA (Belgium)
  • Exact Sciences Corporation (US)
  • Illumina Inc. (US)
  • Sysmex Inostics (US)
  • Bio-Rad Laboratories, Inc. (US)
  • Biocept, Inc. (US)
  • NeoGenomics, Inc. (US)
  • ANGLE plc (UK)
  • Menarini-Silicon Biosystems (Italy)
  • Vortex Biosciences, Inc. (US)
  • Exosome Diagnostics, Inc. (US)
  • Agena Bioscience, Inc. (US)
  • MedGenome Inc. (US)
  • Epigenomics AG (Germany)
  • Personal Genome Diagnostics, Inc. (US)

Research Coverage:

This report provides a detailed picture of the global liquid biopsymarket. It aims at estimating the size and future growth potential of the market across different segments, such as product& service, clinical application, technology, circulating biomarkers, application, and end user. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall liquid biopsy market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, andchallenges.

Product Code: MD 4456

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    • 1.2.2 MARKETS COVERED
    • FIGURE 1 LIQUID BIOPSY MARKET SEGMENTATION
    • 1.2.3 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 2 LIQUID BIOPSY MARKET: RESEARCH DESIGN
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LIQUID BIOPSY MARKET)
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast (2021-2026)
      • 2.3.1.4 CAGR projections
    • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 7 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE
  • 2.6 ASSUMPTIONS FOR THE STUDY
  • 2.7 LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • 2.8.1 RISK ASSESSMENT: LIQUID BIOPSY MARKET
  • 2.9 GROWTH RATE ASSUMPTIONS
  • 2.10 COVID-19 HEALTH ASSESSMENT
  • 2.11 COVID-19 ECONOMIC ASSESSMENT
  • 2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
    • FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
    • FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
  • 2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 11 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 12 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2021 VS. 2026 (USD MILLION)
    • FIGURE 13 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    • FIGURE 14 LIQUID BIOPSY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 15 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 16 LIQUID BIOPSY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    • FIGURE 17 LIQUID BIOPSY MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 LIQUID BIOPSY MARKET OVERVIEW
    • FIGURE 18 THE RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE LIQUID BIOPSY MARKET
  • 4.2 LIQUID BIOPSY MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
    • FIGURE 19 THE ASSAY KITS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
  • 4.3 LIQUID BIOPSY MARKET SHARE, BY CIRCULATING BIOMARKERS, 2021 VS. 2026
    • FIGURE 20 THE CIRCULATING TUMOR CELLS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
  • 4.4 LIQUID BIOPSY MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
    • FIGURE 21 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
  • 4.5 LIQUID BIOPSY MARKET SHARE, BY APPLICATION, 2021 VS. 2026
    • FIGURE 22 CANCER APPLICATIONS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
  • 4.6 LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2021 VS. 2026
    • FIGURE 23 THERAPY SELECTION SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • 4.7 LIQUID BIOPSY MARKET SHARE, BY END USER, 2021 VS. 2026
    • FIGURE 24 REFERENCE LABORATORIES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
  • 4.8 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 25 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE LIQUID BIOPSY MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 26 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence and prevalence of cancer
    • TABLE 1 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
      • 5.2.1.2 Cancer awareness initiatives undertaken by global health organizations
      • 5.2.1.3 Increasing preference for noninvasive treatment procedures
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 The lower sensitivity of certain liquid biopsies
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 The growing significance of companion diagnostics
      • 5.2.3.2 Growth opportunities in emerging countries
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Unclear reimbursement scenario
  • 5.3 IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET
  • 5.4 REALISTIC, PESSIMISTIC, AND OPTIMISTIC SCENARIOS
    • 5.4.1 LIQUID BIOPSY MARKET
    • FIGURE 27 REALISTIC SCENARIO
    • FIGURE 28 PESSIMISTIC SCENARIO
    • FIGURE 29 OPTIMISTIC SCENARIO
  • 5.5 PRICING ANALYSIS
    • TABLE 2 PRICE OF LIQUID BIOPSY PRODUCTS (2021)
  • 5.6 PATENT ANALYSIS
    • 5.6.1 PATENT ANALYSIS OF CIRCULATING BIOMARKERS
  • 5.7 VALUE CHAIN ANALYSIS
    • FIGURE 30 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE
    • FIGURE 31 DISTRIBUTION-A STRATEGY PREFERRED BY PROMINENT COMPANIES
  • 5.8 ECOSYSTEM ANALYSIS OF THE LIQUID BIOPSY MARKET
    • FIGURE 32 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 3 LIQUID BIOPSY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 DEGREE OF COMPETITION
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 NORTH AMERICA
      • 5.10.1.1 US
      • 5.10.1.2 Canada
    • 5.10.2 EUROPE
    • 5.10.3 ASIA PACIFIC
      • 5.10.3.1 China
      • 5.10.3.2 Japan
    • 5.10.4 LATIN AMERICA
      • 5.10.4.1 Brazil
      • 5.10.4.2 Mexico
    • 5.10.5 MIDDLE EAST
    • 5.10.6 AFRICA
  • 5.11 TECHNOLOGY ANALYSIS
  • 5.12 PESTLE ANALYSIS
  • 5.13 TRADE ANALYSIS
    • 5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
      • 5.13.1.1 Import data for diagnostic and laboratory reagents, by country, 2016-2020 (USD Million)
      • 5.13.1.2 Import data for diagnostic and laboratory reagents, by country, 2016-2020 (Tons)
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
    • 5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS
    • 5.14.2 REVENUE SHIFT FOR THE LIQUID BIOPSY MARKET

6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 4 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
  • 6.2 ASSAY KITS
    • 6.2.1 REPEATED REQUIREMENT PURCHASES OF ASSAY KITS TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 5 KEY PRODUCTS IN THE ASSAY KITS MARKET
    • TABLE 6 LIQUID BIOPSY MARKET FOR ASSAY KITS, BY REGION, 2019-2026 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH OF THIS SEGMENT
    • TABLE 7 KEY PRODUCTS IN THE INSTRUMENTS MARKET
    • TABLE 8 LIQUID BIOPSY MARKET FOR INSTRUMENTS, BY REGION, 2019-2026 (USD MILLION)
  • 6.4 SERVICES
    • 6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT THE MARKET GROWTH
    • TABLE 9 LIQUID BIOPSY MARKET FOR SERVICES, BY REGION, 2019-2026 (USD MILLION)

7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS

  • 7.1 INTRODUCTION
    • 7.1.1 PRIMARY NOTES
      • 7.1.1.1 Key industry insights
    • TABLE 10 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
  • 7.2 CIRCULATING TUMOR CELLS (CTC)
    • 7.2.1 BENEFITS OF EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF THE OVERALL TUMOR BURDEN TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 11 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2019-2026 (USD MILLION)
  • 7.3 CIRCULATING TUMOR DNA (CTDNA)
    • 7.3.1 CTDNA ANALYSIS CAN SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS, THUS LEADING TO EARLY-STAGE DETECTION OF CANCER
    • TABLE 12 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2019-2026 (USD MILLION)
  • 7.4 CELL-FREE DNA (CFDNA)
    • 7.4.1 APPLICATION OF CFDNA IN PRENATAL SCREENING IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 13 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2019-2026 (USD MILLION)
  • 7.5 EXTRACELLULAR VESICLES (EVS)
    • 7.5.1 EVS ARE STABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES, THUS ENSURING THE GROWTH OF THIS SEGMENT
    • TABLE 14 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2019-2026 (USD MILLION)
  • 7.6 OTHER CIRCULATING BIOMARKERS
    • TABLE 15 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2019-2026 (USD MILLION)

8 LIQUID BIOPSY MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • 8.1.1 PRIMARY NOTES
      • 8.1.1.1 Key industry insights
    • TABLE 16 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
  • 8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
    • 8.2.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 17 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, 2019-2026 (USD MILLION)
  • 8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS
    • 8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 18 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, 2019-2026 (USD MILLION)

9 LIQUID BIOPSY MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 19 LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
  • 9.2 CANCER APPLICATIONS
    • TABLE 20 CANCER INCIDENCE, BY REGION, 2020 VS. 2040 (MILLION)
    • TABLE 21 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 22 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
    • 9.2.1 LUNG CANCER
      • 9.2.1.1 Increasing prevalence of lung cancer to propel the market growth
    • TABLE 23 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 24 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2019-2026 (USD MILLION)
    • 9.2.2 BREAST CANCER
      • 9.2.2.1 Increasing government funding for breast cancer research is expected to drive the market growth
    • TABLE 25 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 26 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2019-2026 (USD MILLION)
    • 9.2.3 COLORECTAL CANCER
      • 9.2.3.1 Increasing prevalence of colorectal cancer to propel the market growth
    • TABLE 27 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 28 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2019-2026 (USD MILLION)
    • 9.2.4 PROSTATE CANCER
      • 9.2.4.1 Growing number of prostate cancer patients to drive the growth of this market
    • TABLE 29 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 30 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2019-2026 (USD MILLION)
    • 9.2.5 MELANOMA
      • 9.2.5.1 Increasing need for the early diagnosis of genetically mutated tumors to drive market growth
    • TABLE 31 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 32 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2019-2026 (USD MILLION)
    • 9.2.6 OTHER CANCERS
    • TABLE 33 GLOBAL CANCER INCIDENCE, 2020
    • TABLE 34 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2019-2026 (USD MILLION)
  • 9.3 NON-CANCER APPLICATIONS
    • 9.3.1 APPLICATIONS OF LIQUID BIOPSY FOR NIPT AND ORGAN TRANSPLANTATION DIAGNOSIS DRIVES THE GROWTH OF THIS SEGMENT
    • TABLE 35 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2019-2026 (USD MILLION)

10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION

  • 10.1 INTRODUCTION
    • TABLE 36 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
  • 10.2 THERAPY SELECTION
    • 10.2.1 INCREASING PREFERENCE DUE TO NONINVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 37 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2019-2026 (USD MILLION)
  • 10.3 TREATMENT MONITORING
    • 10.3.1 LIQUID BIOPSY FOR TREATMENT MONITORING QUANTITATIVELY CALCULATES THE CONCENTRATION OF CANCER-RELATED MUTATIONS
    • TABLE 38 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2019-2026 (USD MILLION)
  • 10.4 RECURRENCE MONITORING
    • 10.4.1 THE ABILITY TO DETECT CANCER MUTATION THROUGH CTDNA IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 39 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2019-2026 (USD MILLION)
  • 10.5 EARLY CANCER SCREENING
    • 10.5.1 POTENTIAL OF LIQUID BIOPSY IN THE DETECTION OF CANCER AT EARLY STAGES TO DRIVE MARKET GROWTH
    • TABLE 40 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2019-2026 (USD MILLION)

11 LIQUID BIOPSY MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 41 LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 11.2 REFERENCE LABORATORIES
    • 11.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES DRIVES THE GROWTH OF THIS SEGMENT
    • TABLE 42 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2019-2026 (USD MILLION)
  • 11.3 HOSPITALS AND PHYSICIAN LABORATORIES
    • 11.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING THE GROWTH OF THIS SEGMENT
    • TABLE 43 LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY REGION, 2019-2026 (USD MILLION)
  • 11.4 ACADEMIC & RESEARCH CENTERS
    • 11.4.1 GROWING FOCUS OF RESEARCH IN THE DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
    • TABLE 44 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2019-2026 (USD MILLION)
  • 11.5 OTHER END USERS
    • TABLE 45 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2019-2026 (USD MILLION)

12 LIQUID BIOPSY MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 46 LIQUID BIOPSY MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 12.2 NORTH AMERICA
    • TABLE 47 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020, BY TYPE OF CANCER
    • FIGURE 33 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
    • TABLE 48 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 49 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 50 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 51 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 52 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 53 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 54 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 12.2.1 US
      • 12.2.1.1 The increasing prevalence of cancer is a key factor expected to drive market growth in the US
    • TABLE 55 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 56 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 57 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 58 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 59 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 60 US: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 12.2.2 CANADA
      • 12.2.2.1 The availability of various cancer screening programs in Canada is expected to drive market growth in Canada
    • TABLE 61 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 62 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 63 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 64 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 65 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 66 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 12.3 EUROPE
    • TABLE 67 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 68 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 69 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 70 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 71 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 72 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 73 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 12.3.1 GERMANY
      • 12.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany
    • TABLE 74 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 75 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 76 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 77 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 78 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 79 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 12.3.2 UK
      • 12.3.2.1 Increasing number of diagnostic laboratories in the UK to propel the market growth
    • TABLE 80 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 81 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 82 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 83 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 84 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 85 UK: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 12.3.3 FRANCE
      • 12.3.3.1 Rising R&D expenditure in France to drive the market growth
    • TABLE 86 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 87 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 88 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 89 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 90 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 91 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 12.3.4 REST OF EUROPE
    • TABLE 92 ROE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 93 ROE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 94 ROE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 95 ROE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 96 ROE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 97 ROE: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 12.4 ASIA PACIFIC
    • FIGURE 34 APAC: LIQUID BIOPSY MARKET SNAPSHOT
    • TABLE 98 APAC: LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 99 APAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 100 APAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 101 APAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 102 APAC: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 103 APAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 104 APAC: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 12.4.1 CHINA
      • 12.4.1.1 Growing public access to advanced healthcare facilities to drive the market growth in China
    • TABLE 105 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 106 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 107 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 108 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 109 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 110 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 12.4.2 JAPAN
      • 12.4.2.1 Universal healthcare reimbursement policy to drive the market growth in Japan
    • TABLE 111 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 112 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 113 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 114 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 115 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 116 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 12.4.3 INDIA
      • 12.4.3.1 Increasing private & public investments in the country's healthcare system is expected to drive the market growth
    • TABLE 117 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 118 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 119 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 120 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 121 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 122 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 12.4.4 REST OF ASIA PACIFIC
    • TABLE 123 ROAPAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 124 ROAPAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 125 ROAPAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 126 ROAPAC: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 127 ROAPAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 128 ROAPAC: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 12.5 REST OF THE WORLD
    • TABLE 129 ROW: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • TABLE 130 ROW: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
    • TABLE 131 ROW: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
    • TABLE 132 ROW: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 133 ROW: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 134 ROW: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW
  • 13.2 KEY PLAYER STRATEGIES
    • 13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE LIQUID BIOPSY MARKET
    • TABLE 135 OVERVIEW OF STRATEGIES DEPLOYED BY SOME LIQUID BIOPSY PRODUCT MANUFACTURING COMPANIES
  • 13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 35 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE LIQUID BIOPSY MARKET
  • 13.4 MARKET SHARE ANALYSIS
    • FIGURE 36 LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER (2020)
    • TABLE 136 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION
  • 13.5 COMPANY EVALUATION QUADRANT
    • 13.5.1 LIST OF EVALUATED VENDORS
    • 13.5.2 STARS
    • 13.5.3 EMERGING LEADERS
    • 13.5.4 PERVASIVE PLAYERS
    • 13.5.5 PARTICIPANTS
    • FIGURE 37 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
  • 13.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 STARTING BLOCKS
    • 13.6.3 RESPONSIVE COMPANIES
    • 13.6.4 DYNAMIC COMPANIES
    • FIGURE 38 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
  • 13.7 COMPETITIVE BENCHMARKING
    • FIGURE 39 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE LIQUID BIOPSY MARKET
    • TABLE 137 COMPANY PRODUCT TYPE FOOTPRINT
    • TABLE 138 COMPANY GEOGRAPHICAL FOOTPRINT
  • 13.8 COMPETITIVE SCENARIO
    • 13.8.1 PRODUCT LAUNCHES AND REGULATORY APPROVALS
    • TABLE 139 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
    • 13.8.2 DEALS
    • TABLE 140 KEY DEALS
    • 13.8.3 LIQUID BIOPSY: OTHER DEVELOPMENTS
    • TABLE 141 OTHER KEY DEVELOPMENTS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 14.1.1 QIAGEN N.V.
    • TABLE 142 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
    • 14.1.2 F. HOFFMANN-LA ROCHE
    • TABLE 143 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
    • FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
    • 14.1.3 MYRIAD GENETICS, INC.
    • TABLE 144 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
    • FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020)
    • 14.1.4 THERMO FISHER SCIENTIFIC INC.
    • TABLE 145 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
    • 14.1.5 GUARDANT HEALTH, INC.
    • TABLE 146 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
    • FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2020)
    • 14.1.6 BIO-RAD LABORATORIES
    • TABLE 147 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 45 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
    • 14.1.7 ILLUMINA, INC.
    • TABLE 148 ILLUMINA, INC.: BUSINESS OVERVIEW
    • FIGURE 46 ILLUMINA: COMPANY SNAPSHOT (2020)
    • 14.1.8 EXACT SCIENCES
    • TABLE 149 EXACT SCIENCES: BUSINESS OVERVIEW
    • FIGURE 47 EXACT SCIENCES: COMPANY SNAPSHOT (2020)
    • 14.1.9 SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION)
    • TABLE 150 SYSMEX INOSTICS: BUSINESS OVERVIEW
    • FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
    • 14.1.10 BIOCEPT, INC.
    • TABLE 151 BIOCEPT, INC.: BUSINESS OVERVIEW
    • FIGURE 49 BIOCEPT, INC.: COMPANY SNAPSHOT (2020)
    • 14.1.11 MDX HEALTH
    • TABLE 152 MDX HEALTH: BUSINESS OVERVIEW
    • FIGURE 50 MDX HEALTH: COMPANY SNAPSHOT (2020)
  • 14.2 OTHER PLAYERS
    • 14.2.1 NEOGENOMICS, INC.
    • 14.2.2 ANGLE PLC
    • 14.2.3 EPIGENOMICS AG
    • 14.2.4 MENARINI-SILICON BIOSYSTEMS
    • 14.2.5 VORTEX BIOSCIENCES, INC.
    • 14.2.6 EXOSOME DIAGNOSTICS, INC.
    • 14.2.7 MEDGENOME INC.
    • 14.2.8 AGENA BIOSCIENCE, INC.
    • 14.2.9 PERSONAL GENOME DIAGNOSTICS, INC.
    • 14.2.10 FREENOME HOLDINGS, INC.
    • 14.2.11 STRAND LIFE SCIENCES
    • 14.2.12 LUNGLIFE AI, INC.
    • 14.2.13 LUCENE HEALTH INC.
    • 14.2.14 ANPAC BIO-MEDICAL SCIENCE CO., LTD.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 AVAILABLE CUSTOMIZATIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS